Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

3 Great Income Stocks that Could Double their Dividends
3 Great Income Stocks that Could Double their Dividends
When searching for income stocks, investors should always study their payout ratios -- the percentage of a company's earnings or free cash flow (FCF) that it spends on dividends. If those ratios....
Like Dividends? This Stock Just Increased Its Payout for the 50th Year in a Row
Like Dividends? This Stock Just Increased Its Payout for the 50th Year in a Row
Federal Realty Investment Trust (NYSE: FRT) is one of the oldest real estate investment trusts, or REITs, and invests in shopping center properties located in seven major U.S. markets. Not only....
How Johnson & Johnson Makes Most of Its Money
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
How Johnson & Johnson Makes Most of Its Money
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in....
3 Cheap Stocks You Can Buy Right Now
3 Cheap Stocks You Can Buy Right Now
With the market hitting record highs, it's getting more difficult to find attractively priced stocks to invest in. However, thanks to industry-specific weakness, there are still some long-term....
Can Cameco Corp's 4.1% Dividend Yield Survive?
Can Cameco Corp's 4.1% Dividend Yield Survive?
About three months ago I argued that the world's leading uranium producer would be better off suspending its dividend than maintaining it. While Cameco Corp (NYSE: CCJ) shareholders certainly....
Can Cameco Corp's 4.1% Dividend Yield Survive?
Can Cameco Corp's 4.1% Dividend Yield Survive?
About three months ago I argued that the world's leading uranium producer would be better off suspending its dividend than maintaining it. While Cameco Corp (NYSE: CCJ) shareholders certainly....
Losing Sleep Over Your Portfolio? Consider This Stock
Losing Sleep Over Your Portfolio? Consider This Stock
Some investors prefer stability. The more volatility in their portfolios, the less they sleep at night. Sound like you? If so, I've got good news: One of the world's best businesses is still....
Losing Sleep Over Your Portfolio? Consider This Stock
Losing Sleep Over Your Portfolio? Consider This Stock
Some investors prefer stability. The more volatility in their portfolios, the less they sleep at night. Sound like you? If so, I've got good news: One of the world's best businesses is still....
Losing Sleep Over Your Portfolio? Consider This Stock
Losing Sleep Over Your Portfolio? Consider This Stock
Some investors prefer stability. The more volatility in their portfolios, the less they sleep at night. Sound like you? If so, I've got good news: One of the world's best businesses is still....
3 "Amazoned" Retail Stocks I'd Hate to Buy
3 "Amazoned" Retail Stocks I'd Hate to Buy
Being "Amazoned" means that Amazon.com's (NASDAQ: AMZN) ever-expanding e-commerce ecosystem is steamrolling a company. That list is growing by the day, with sluggish brick-and-mortar traffic....
3 "Amazoned" Retail Stocks I'd Hate to Buy
3 "Amazoned" Retail Stocks I'd Hate to Buy
Being "Amazoned" means that Amazon.com's (NASDAQ: AMZN) ever-expanding e-commerce ecosystem is steamrolling a company. That list is growing by the day, with sluggish brick-and-mortar traffic....
1 Thing You Can Do to Turbocharge Your Retirement Savings
1 Thing You Can Do to Turbocharge Your Retirement Savings
Being able to consistently contribute enough to your retirement savings accounts is the single most important aspect of any retirement plan, but it's also by far the most challenging. So finding a....
Why Things Look Good for Broadcom
Why Things Look Good for Broadcom
Broadcom (NASDAQ: AVGO) has been a stock market darling this year -- up roughly 45% -- thanks to consistent financial growth and rumors of windfall gains from Apple's (NASDAQ: AAPL) next iPhone....
Why Things Look Good for Broadcom
Why Things Look Good for Broadcom
Broadcom (NASDAQ: AVGO) has been a stock market darling this year -- up roughly 45% -- thanks to consistent financial growth and rumors of windfall gains from Apple's (NASDAQ: AAPL) next iPhone....
Why Things Look Good for Broadcom
Why Things Look Good for Broadcom
Broadcom (NASDAQ: AVGO) has been a stock market darling this year -- up roughly 45% -- thanks to consistent financial growth and rumors of windfall gains from Apple's (NASDAQ: AAPL) next iPhone....
Why Things Look Good for Broadcom
Why Things Look Good for Broadcom
Broadcom (NASDAQ: AVGO) has been a stock market darling this year -- up roughly 45% -- thanks to consistent financial growth and rumors of windfall gains from Apple's (NASDAQ: AAPL) next iPhone....
iPhone 8: Is This Feature Its "Crown Jewel"?
iPhone 8: Is This Feature Its "Crown Jewel"?
Apple's (NASDAQ: AAPL) upcoming iPhone is important. Investors are looking to the next flagship version of the device to help the segment return to more meaningful growth. Raising the stakes ahead....
iPhone 8: Is This Feature Its "Crown Jewel"?
iPhone 8: Is This Feature Its "Crown Jewel"?
Apple's (NASDAQ: AAPL) upcoming iPhone is important. Investors are looking to the next flagship version of the device to help the segment return to more meaningful growth. Raising the stakes ahead....
iPhone 8: Is This Feature Its "Crown Jewel"?
iPhone 8: Is This Feature Its "Crown Jewel"?
Apple's (NASDAQ: AAPL) upcoming iPhone is important. Investors are looking to the next flagship version of the device to help the segment return to more meaningful growth. Raising the stakes ahead....
iPhone 8: Is This Feature Its "Crown Jewel"?
iPhone 8: Is This Feature Its "Crown Jewel"?
Apple's (NASDAQ: AAPL) upcoming iPhone is important. Investors are looking to the next flagship version of the device to help the segment return to more meaningful growth. Raising the stakes ahead....
3 Stocks With Microsoft-Like Return Potential
3 Stocks With Microsoft-Like Return Potential
Microsoft (NASDAQ: MSFT) investors enjoyed nearly a 100-fold return in the 1990s. Shares bought at the start of the decade had delivered a stunning 9,300% gain when the Y2K bug was dodging the....